TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03257800
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group which received intravenously the same volume with normal saline one minute prior propofol 3mg.kg-¹ and 1 min before LMA insertion in propofol group
Study: NCT01505764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets identical in appearance to active tablets; oral administration once a day for 84 days, at least 1 hour before the first meal of the day.
Study: NCT01717053
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH analog (at discretion of treating physician) will be administered over 6 months (for example, leuprolide acetate 22.5mg IM or goserelin acetate 10.8mg SC given every 3 months for 2 doses).
Study: NCT00757198
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: remifentanil infusion
Study: NCT01595022
Drug: Placebo: Flexi ring FR01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine device, inserted once for 3 months
Study: NCT01595022
Drug: Placebo: Flexi ring FR20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine device, inserted once for 3 months
Study: NCT00662298
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg of prednisolone once a day for 14 days
Study: NCT05782309
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessement, supplementation placebo for 30 days with either Placebo or Flavanols, Re-assessment
Study: NCT00902486
Drug: INCB028050
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg capsules QD
Study: NCT02527603
Drug: Anti-Inflammatory Agents, Non-Steroidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will be administered a dose of NSAI intra-muscular or orally (Dexketoprofen, Enantyum®) it is part of the normal treatment of these patients to cope with pain.
Study: NCT00902486
Drug: INCB028050
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 mg capsules QD
Study: NCT00902486
Drug: INCB028050
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg capsule QD
Study: NCT00902486
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching INCB028050 QD
Study: NCT01758536
Drug: Huatuo Zaizao Pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: A tens of herbs botanical drug product 12 gram (g) in 72 mini pills formulation. It is to be used as 12 g each time, twice daily.
Study: NCT00413985
Drug: Nutrient-enriched human milk
Normalized name: human milk preparation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03007810
Drug: Hemay005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized into 6 cohorts(10mg, 20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
Study: NCT03007810
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized into 5 cohorts(20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
Study: NCT00803673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo '719
Study: NCT00366067
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04059536
Drug: Acetylsalicylic Acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT04059536
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Injection
Study: NCT01131013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo in capsules administered as a single oral dose.
Study: NCT03085914
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin
Study: NCT03085914
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide
Study: NCT03594110
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken daily with or without food
Study: NCT03090152
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPCA: Saline.
Study: NCT04494100
Drug: Lidocaine + Epinephrine
Normalized name: epinephrine / lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: WALANT technique with 1% lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine
Study: NCT00228176
Drug: Placebo (for Rimonabant)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral administration
Study: NCT04504851
Drug: Rosuvastatin 10mg
Normalized name: ROSUVASTATIN 10MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg of Rosuvastatin in the Intensive Phase of Therapy (8 weeks)
Study: NCT01786070
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00317967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg pills daily
Study: NCT00505076
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets placebo BID
Study: NCT02215941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04076098
Drug: Minocycline Hydrochloride
Normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of Periocline gel into the periodontal pockets will be carried out until it overflows the pockets
Study: NCT01541397
Drug: Sapropterin
Normalized name: Sapropterin
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy
Study: NCT03472846
Drug: Prolia, 60 Mg/mL Subcutaneous Solution
Normalized name: Prolia, 60 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: antiresorptive treatment with Prolia
Study: NCT00641511
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: once per day placebo capsules
Study: NCT00752401
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral placebo solution matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for one year. Treatment starts on day 5 after kidney transplantation.
Study: NCT00710125
Drug: GPX-150 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses starting at the dose of 14 mg/m2 and increasing to the dose of 265 mg/m2 will be administered IV once every 3 weeks for up to 8 cycles of treatment. Patients who have previously received an anthracycline are limited to 4 cycles of treatment.
Study: NCT01547559
Drug: part1:EAC-T
Approvals — FDA: no, EMA: no, PMDA: no
Description: esomeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily followed by gastric mucosal protective therapy with teprenone 50mg three times daily for 11 weeks
Study: NCT01547559
Drug: part1:EA-EMC-T
Approvals — FDA: no, EMA: no, PMDA: no
Description: esomeprazole 20 mg plus amoxicillin 1 g, twice daily for 5 days, then esomeprazole 20 mg with clarithromycin 500 mg and metronidazole 500 mg, twice daily for another 5 consecutive days) followed by teprenone 50mg three times daily until 12 weeks
Study: NCT01547559
Drug: part2:GGA group
Approvals — FDA: no, EMA: no, PMDA: no
Description: GGA 50mg three times daily plus diclofenac sodium 75mg once a day for patients with rheumatic diseases.
Study: NCT02737891
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01342237
Drug: HDCT 1(TTC), HDCT2(MEC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. TTC Topotecan (2 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4) Thiotepa (300 mg/m2 once daily i.v on days -8, -7, -6) Carboplatin (500 mg/m2 once daily i.v on days -5, -4, -3) (max. 700 mg/day)~2. MEC Melphalan (140 mg/m2 once daily i.v on day -7, 70 mg/m2 once daily i.v on day -6) Etoposide (200 mg/m2 once daily i.v on days -8, -6) Carboplatin (350 mg/m2 once daily i.v on days -8, -7, -6, -5)
Study: NCT04369261
Drug: Synovian®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synovian® Inj.
Study: NCT02675556
Drug: Allo-hMSCs
Normalized name: allo-2-hydroxycitric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10\^6 (100 million) allo-hMSCs of cells
Study: NCT02675556
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A
Study: NCT03441373
Drug: XC8 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily during 5 days.
Study: NCT03441373
Drug: XC8 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily during 5 days.
Study: NCT03441373
Drug: XC8 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily during 5 days.
Study: NCT03441373
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily during 5 days.
Study: NCT02424799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
Study: NCT04355585
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given over 1 hour (first tablet followed by second tablet 1 hour later)
Study: NCT01845194
Drug: Codeine
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment period 2:~5 mg Codeine once
Study: NCT01845194
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment period 2:~5 mg Pravastatin once
Study: NCT01845194
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment period 1:~50 mg Caffeine 3x
Study: NCT02987114
Drug: PLT101
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTL 101 (Cannabidiol, CBD) Two piece hard capsules filled with seamless gelatin matrix green beads containing CBD (50 or 100 mg CBD per capsule) The beads should be administered following a meal, mixed with food
Study: NCT03545971
Drug: IBI310
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI310 is anti CTLA-4 antibody
Study: NCT00079365
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00681356
Drug: 4975, 15 and 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct instillation into the surgical site
Study: NCT00681356
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct instillation into the surgical site
Study: NCT01481194
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 IV on day 1 of a 21-day cycle
Study: NCT01481194
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 IV on day 1 of a 21-day cycle
Study: NCT00644085
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of placebo
Study: NCT02080819
Drug: levodopa/carbidopa 400/100 BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa dose escalation (1 week): Days 1-2, one 50/12.5 mg tablet BID; Days 3-4, one 100/25 mg tablet BID; Days 5-6, one 200/50 mg tablet BID; Day 7, one 400/100 mg tablet BID.~Maintenance phase (7 weeks): One 400/100 mg Levodopa/Carbidopa tablet BID or placebo in conjunction with once weekly individual cognitive behavioral therapy plus contingency management for attendance.
Study: NCT01788215
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg/day in divided doses of 100mg twice daily
Study: NCT01912469
Drug: Traumeel
Normalized name: Traumeel
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
Study: NCT01912469
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
Study: NCT04354597
Drug: HCQ & AZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive weekly HCQ 400mg PO and AZ PO 500mg X 3 Days; weekly for 16 weeks.
Study: NCT01630538
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 1.5 mg/kg orally daily for 180 days adjusted for renal function
Study: NCT02636361
Drug: LY900014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (SC)
Study: NCT00612105
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily
Study: NCT01443624
Drug: critical care patients venofer
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg IV in one hour (in critically ill patients the injection could be repeated on day 2 (200mg) and 4 (100mg) depending on treatment
Study: NCT01651962
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01651962
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03730142
Drug: WXFL10030390
Approvals — FDA: no, EMA: no, PMDA: no
Description: WXFL10030390 is a tablet in the form of 0.1mg and 0.5mg, oral, once a day.
Study: NCT01411735
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5mg titrated up to 10mg twice daily.
Study: NCT02428478
Drug: Desipramine
Normalized name: Desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg administered 2 hours before normal sleep time
Study: NCT02428478
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching desipramine administered 2 hours before normal sleep time
Study: NCT00029146
Drug: best medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: best current practice medical therapy
Study: NCT01775397
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT01577082
Drug: CHF1535 200/6 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF 1535 (BDP/FF) 800/24 µg daily during 12 weeks
Study: NCT01577082
Drug: BDP 100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone Dipropionate 800µg daily during 12 weeks
Study: NCT02377661
Drug: Olmesartan medoxomil, amlodipine, hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up-titration of antihypertensive therapy with single pill combinations (comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide) in 4-week intervals if the target blood pressure of \< 140/90 mmHg is not reached at the respective follow-up
Study: NCT00004930
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02692391
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal indomethacin will be administered as 100 mg loading doses following by 5 maintenance doses of 50 mg at internals of 8 hours for total of 48 hours.
Study: NCT02692391
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerin placebo suppositories which are identical in shape, size, color, and packaging to rectal indomethacin
Study: NCT00539188
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, 2 capsules PO AM, 3 capsules PO PM, 6 weeks
Study: NCT05427617
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician chosen treatment
Study: NCT05427617
Drug: Case group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Druggable ctDNA alterations-guided therapy
Study: NCT04636983
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT00272025
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03183739
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally.
Study: NCT00710086
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil intravenous PCA: 0.2μg/kg, lockout time interval 2 minutes, continuous infusion rate 0.2-0.8μg/kg/min.
Study: NCT02916537
Drug: CTT1057
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV dose (370 MBq, or 10 mCi) of CTT1057 followed by combined PET/MR imaging (prostate + whole body).
Study: NCT00637702
Drug: ARRY-334543, EGFR/ErbB2 inhibitor; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose and multiple dose, escalating
Study: NCT03790033
Drug: Ucha-Shinki-Hwan
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Product name : Bosinji Granule Manufacturer : Tsumura \& Co. Ingredient : Bosinji granule 2.5g (Bosinji extract 1.523g)~Bosinji extract is composed of following proportion of ingredient~Rehmannia Root 1.7g Achyranthes Root 1.0g Cornus Fruit 1.0g Dioscorea Rhizome 1.0g Psyllium Husk 1.0g Alisma Rhizome 1.0g Hoelen 1.0g Moutan Root Bark 1.0g Cinnamon Bark 0.3g Pulvis Aconiti Tuberis Purificatum 0.3g
Study: NCT03790033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo granule
Study: NCT03272568
Drug: Recombinant FIX Fc fusion product Alprolix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will get FIX activity corrected from the baseline level to 100-150% with Alprolix on the first day of menstruation at the beginning of the study interventional phase. The first dose of the drug will be given in the clinics via slow injection into a vein (infusion). A short assessment of pharmacokinetics (PK) (4 time-points blood draw: 15 min, 4 hours, 48 hours, 72 hours after the infusion) will be performed (by home nursing or local lab) to assist with subsequent dosing. Single dose of Alprolix likely to be given on day 1 of menstrual period. The subject will then receive three additional PK-adjusted monthly doses of Alprolix (with no less than 21 days interval).
Study: NCT03485300
Drug: Drug or food interactions
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will be in contact with the researcher for any drug added with warfarin in case of other co morbidity conditions and follow up his/her CBC and INR for measuring its effect on warfarin finding out the effect of food on warfarin therapeutic outcome
Study: NCT01008423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to budesonide will be administered as per the dose and schedule specified in the respective arm.
Study: NCT01064375
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One intravenous dose of 300 mg/m2 will be given three days before each vaccination with tetwtCEA DNA
Study: NCT00147836
Drug: Human Insulin NPH (Novolin-N, Novo Nordisk)
Normalized name: insulin isophane
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00147836
Drug: Diamicron and Glucophage
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03800420
Drug: BBT-401-1S first and then Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total 16 week treatment period: The subject takes BBT-401-1S, QD for the first 12 weeks, then placebo for the last 4 weeks.
Study: NCT03800420
Drug: Placebo first and then BBT-401-1S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total 16 week treatment period: The subject takes the placebo, QD for the first 8 weeks, then BBT-401-1S for the last 8 weeks.
Study: NCT03078829
Drug: Treatment with a GnRh agonists
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will be treated with GnRH agonists
Study: NCT00651079
Drug: GSK1247303
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00401687
Drug: Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention for this study was that all patients received a slow bolus injection of diluted DEFINITY during the contrast-enhanced imaging study.
Study: NCT00605956
Drug: NatrOVA Creme Rinse - 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: NatrOVA Creme Rinse - 1% spinosad
Study: NCT00605956
Drug: Blank Patch
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blank Patch
Study: NCT00470509
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 subcutaneous injections on day 0 and 7
Study: NCT01030666
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients of the doxycycline group will take 200 mg doxycycline once a day for 7 days after regenerative therapy of an infrabony defects.
Study: NCT01030666
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients of the doxycycline group will take 200 mg placebo once a day for 7 days after regenerative therapy of an infrabony defects.
Study: NCT01030666
Drug: Ibuprofen 400 mg (if necessary)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg ibuprofen qd was prescribed for patient's comfort if necessary.
Study: NCT00200343
Drug: Ursodeoxycholic acid 150mg / day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid, 150mg/ day, three times a day at meals
Study: NCT00200343
Drug: Ursodeoxycholic acid 600mg / day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid, 600mg/ day, three times a day at meals
Study: NCT00200343
Drug: Ursodeoxycholic acid 900mg / day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid, 900mg/ day, three times a day at meals
Study: NCT01785862
Drug: Ibuprofen 25 mg
Normalized name: diphenhydramine-ibuprofen 25 mg-200 mg oral capsule
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lozenge, Oromucosal administration
Study: NCT01785862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lozenge matching V0498 lozenge, Oromucosal administration
Study: NCT00869726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous, once every six months for 18 months
Study: NCT00558831
Drug: Moisturizing Lotion
Normalized name: MOISTURIZING LOTION
Approvals — FDA: no, EMA: no, PMDA: no